Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB160058 Phase 1 in healthy volunteers
NCT06213818Phase 1Completed
- Sponsor
- Incyte
- Start
- Mar 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of INCB160058 (17 cohorts), sponsored by Incyte. Primary endpoints: Treatment Emergent Adverse Events at 28 days, INCB160058 Pharmacokinetics when administered as solid tablets in Plasma at 5 days and 8 more. Started Mar 2024; status: completed.
02
Drugs
INCB160058
Beyond the preview
Go deeper on NCT06213818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06213818.